Scientists develop multifunctional nano platforms to provide effective methods for the treatment of triple negative breast cancer
AD |
Recently, researchers from the National Nanometer Center developed a multifunctional nano platform (MTO micelles) based on the clinical chemotherapy drug Mitoxantrone, which enables the realization of synergistic mild photothermal chemotherapy.In the study, they encapsulated MTO in nano micelles, effectively inhibiting the growth of triple negative breast cancer
Recently, researchers from the National Nanometer Center developed a multifunctional nano platform (MTO micelles) based on the clinical chemotherapy drug Mitoxantrone, which enables the realization of synergistic mild photothermal chemotherapy.
In the study, they encapsulated MTO in nano micelles, effectively inhibiting the growth of triple negative breast cancer. This mild photothermal chemotherapy formula can down regulate the expression of HSP70, thereby increasing the DNA damage of tumor cells, thus providing a simple and effective method for the treatment of triple negative breast cancer.
Recently, the related paper titled "DNA Damage Inducer Mitoxantrone Amplifies Synergistic Mild PhotothermalChemotherapy for TNBCvia Decreasing Heat Shock Protein 70 Expression" was published onAdvancedScienceGo up [1].
Zuqin Chen is the first author, and Li Fangzhou, Professor Leung Hing Kit of the National Nanotechnology Center and Professor Xiao Yueyong of the 301 Hospital are the co corresponding authors.
It is reported that triple negative breast cancer is a subtype of breast cancer with high intractability and poor prognosis, and there is still a lack of effective Targeted therapy. Therefore, they want to explore a new treatment strategy that utilizes nanotechnology to assist photothermal therapy and achieve the synergistic effect of mild photothermal chemotherapy.
Later, they chose MTO as a chemotherapy drug and photothermal conversion agent because of its excellent near-infrared absorption and anti-tumor activity, and it has been used in clinical treatment.
In the study, the research team designed a series of experiments, including the preparation and characterization of MTO micelles, the in vitro and in vivo photothermal conversion efficiency of MTO micelles, the in vitro and in vivo drug release kinetics of MTO micelles, the in vitro and in vivo cytotoxicity and anti-tumor effects of MTO micelles, the in vivo drug distribution and metabolism of MTO micelles, and the mild photothermal chemotherapy synergistic mechanism of MTO micelles.
Subsequently, they analyzed and discussed the experimental data and results, and found that MTO micelles have the following characteristics:
Firstly, MTO micelles have a smaller particle size (about 100nm), higher drug loading capacity (about 20%), and better stability;
Thirdly, MTO micelles can accumulate at tumor sites through enhanced permeation and retention effects, and can release more MTO under mild high temperatures;
Fourthly, MTO micelles can achieve synergistic mild photothermal chemotherapy, which can improve the apoptosis rate and necrosis rate of triple negative breast cancer cells, thereby inhibiting the growth of triple negative breast cancer tumors;
Fifthly, MTO micelles can enhance DNA damage and lead to downregulation of HSP70 expression, which in turn can weaken the heat tolerance of tumors and enhance the effectiveness of mild photothermal therapy;
Sixth, MTO micelles have good biocompatibility and biodegradability, and can be metabolized and excreted in the body.
In addition, the enhancement of DNA damage leads to a downregulation of the expression of heat shock protein 70 (HSP70), which in turn weakens the tumor's heat tolerance and enhances the effectiveness of mild photothermal therapy.
The above findings reveal the synergistic mechanism of MTO micelles in mild photothermal chemotherapy, and provide a new idea for the treatment of triple negative breast cancer.
Secondly, this work addresses two challenges currently faced by nanotechnology assisted photothermal therapy: firstly, the heat resistance caused by photothermal therapy limits the therapeutic effect of photothermal therapy; Secondly, there is uncertainty in the physiological metabolism of existing photothermal nanoparticles, which affects their clinical application.
In this study, MTO micelles were used to achieve mild photothermal chemotherapy, which not only avoided normal tissue damage caused by high temperature, but also reduced the production of heat resistance.
At the same time, MTO micelles are prepared based on clinical drug MTO and have good biocompatibility and biodegradability, which is beneficial for metabolism and excretion in vivo.
Due to the fact that MTO micelles are prepared based on clinical chemotherapy drug MTO, they can achieve mild photothermal chemotherapy, avoiding normal tissue damage caused by high temperature and reducing the production of heat resistance. In several years, this achievement has the following potential applications:
First, it can be used for the treatment of triple negative breast cancer. Triple negative breast cancer is a subtype of breast cancer with high intractability and poor prognosis. At present, there is no effective Targeted therapy. MTO micelles can achieve synergistic mild photothermal chemotherapy, thereby improving the cure rate and survival rate of triple negative breast cancer patients.
Secondly, it can be used for the treatment of other types of cancer. MTO is a synthetic anthraquinone drug with anti-tumor, immunomodulatory, and anti-inflammatory effects. Currently, MTO has been used to treat acute non lymphocytic leukemia, hormone resistant prostate cancer, ovarian cancer, gastric cancer, and liver cancer. MTO micelles can enhance the chemotherapy effect of MTO and provide a synergistic effect of photothermal therapy, which may also have therapeutic effects on other types of cancer.
Third, it can be used for the treatment of Multiple sclerosis. Multiple sclerosis is an autoimmune neurodegenerative disease, which can lead to dysfunction of the central nervous system. Previously, MTO has been used to treat secondary progressive Multiple sclerosis, because it can inhibit the activation and proliferation of T cells and B cells, and reduce the damage of nerve fiber sheath. MTO micelles are expected to provide a safer and more effective treatment for Multiple sclerosis, because it can reduce the toxicity of MTO to the heart and enhance the neuroprotective effect through Photothermal effect.
Next, they will continue to optimize the preparation and characterization methods of MTO micelles, improve their stability, drug loading, and photothermal conversion efficiency, and reduce the toxicity and side effects of MTO micelles.
It will also explore the molecular details of MTO micelles' mild photothermal chemotherapy synergistic mechanism, reveal the mechanism of MTO micelles' influence on the signal pathway, gene expression and protein level of triple negative breast cancer cells, and explore how to regulate the expression and function of HSP70 in the end.
At the same time, the scope of application of the mild photothermal chemotherapy synergistic effect of MTO micelles will also be expanded, and the therapeutic effect of MTO micelles on other types of cancer cells and tumor models will be tested, as well as their safety against normal cells and tissues.
In addition, the research group will also promote the clinical transformation of MTO micelles, and evaluate the therapeutic effect and safety of MTO micelles on human triple negative breast cancer patients through more preclinical and clinical trials, so as to provide better treatment options for triple negative breast cancer patients.
References
1. Chen, Z., Li, S., Li, F., Qin, C., Li, X., Qing, G.,...& Xiao, Y (2023). DNADAmageInducerMitoxantroneAmplifiesSynergisticMid - PhotothermalChemotherapyforTNBCvia DecreasingHeatShockProtein70ExpressionAdvancedScience2206707
Disclaimer: The content of this article is sourced from the internet. The copyright of the text, images, and other materials belongs to the original author. The platform reprints the materials for the purpose of conveying more information. The content of the article is for reference and learning only, and should not be used for commercial purposes. If it infringes on your legitimate rights and interests, please contact us promptly and we will handle it as soon as possible! We respect copyright and are committed to protecting it. Thank you for sharing.(Email:[email protected])
Mobile advertising space rental |
Tag: Scientists develop multifunctional nano platforms to provide effective methods
The account was suspended just after sending two orders! A hot day, a day for reporters to experience delivery riders
NextThe iPhone 15 series cannot be concealed, Apple A17+8GB+1TB, with a new high selling price
Guess you like
-
The Facial Swelling of Shenzhou 18 Astronauts: The Physiological Cost of Space Exploration and Future ChallengesDetail
2024-11-17 08:03:04 1
-
Xiaomi Automobile Unveils Intelligent Chassis Pre-Research Technology, Ushering in a New Era of "Human-Car-Home Full Ecosystem"Detail
2024-11-14 11:24:27 1
-
Douyin E-commerce Double 11 Data Report: Merchants Businesses Grow, Consumer Trends EmergeDetail
2024-11-14 11:23:11 1
-
New Trends in SOE Reform: Focusing on Five Values to Build a "Living Organism"Detail
2024-11-14 11:19:26 1
-
CATL Chairman Zeng Yuqun: Musk Doesn't Understand Batteries, Tesla's Bet on Cylindrical Batteries is Doomed to FailDetail
2024-11-13 18:47:38 1
-
China Eastern Airlines Technology and Thales Renew Cooperation Agreement, Deepening Avionics Maintenance PartnershipDetail
2024-11-13 16:40:50 1
- Detail
- Detail
- Detail
-
Li Jiaqi's Livestream Double 11 Report: Domestic Brands Surge, Winter Warmer Economy BoomsDetail
2024-11-12 11:07:26 11
-
BYD: Plug-in Hybrids "To the Rescue," Behind the Price War Lies a "Davis Double-Click" in ProfitabilityDetail
2024-11-12 10:49:05 1
-
The Rise of Online Livestreamers: A Mass Career with 15 Million Dream Chasers in Live RoomsDetail
2024-11-11 15:27:33 11
-
Microsoft "Mail and Calendar" app will be officially discontinued at the end of next year, users need to migrate to the new OutlookDetail
2024-11-10 14:53:36 11
- Detail
-
Alibaba Pictures' Phoenix Cloud Intelligence International Edition iCIRENA Expands to Hong Kong and Macau, Bringing Technological Upgrades to CinemasDetail
2024-11-09 11:22:49 11
-
From Daughter of Heaven to Ordinary Mom: Liu Yang's Space Dream and the Diversification of LifeDetail
2024-11-09 10:36:56 1
- Detail
-
Global Focus: CIIE Signs Deals Worth Over 10 Billion, 6G Technology Takes the Lead, Avian Flu Outbreak Ravages, Typhoon "Ginkgo" ApproachesDetail
2024-11-08 14:39:05 1
-
The Battle for the Smartphone Throne: Apple, Samsung, and Huawei Vie for DominanceDetail
2024-11-07 21:01:50 1
-
Why Chinese Astronauts Lie Down When Exiting the Capsule? The Truth is Not InferiorityDetail
2024-11-07 00:51:26 11